<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03129139</url>
  </required_header>
  <id_info>
    <org_study_id>Minnelide 101</org_study_id>
    <nct_id>NCT03129139</nct_id>
  </id_info>
  <brief_title>A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors</brief_title>
  <acronym>Minnelide 101</acronym>
  <official_title>A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minneamrita Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Translational Drug Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Minneamrita Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and
      Pharmacodynamic Study of Minnelide™Capsules given daily for 21 days followed by 7 days off
      schedule in patients with Advanced Solid Tumors
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Related Adverse Events</measure>
    <time_frame>24 months</time_frame>
    <description>as assessed by CTCAE V4 .03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-tumor activity</measure>
    <time_frame>24 months</time_frame>
    <description>RECIST 1.1</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Advanced Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Prostate Cancer Metastatic</condition>
  <condition>Colo-rectal Cancer</condition>
  <condition>Solid Tumor</condition>
  <condition>Solid Carcinoma</condition>
  <condition>Solid Carcinoma of Stomach</condition>
  <condition>Cancer of Stomach</condition>
  <arm_group>
    <arm_group_label>Regimen A (monotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Minnelide™ Capsules will be given as a single agent orally once daily x 21 days followed by a 7-day off schedule. One cycle will equal 28 days. MinnelideTM Capsules should be given with the patient in a fasting state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen B (combination)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MinnelideTM Capsules will be given orally once daily x 21 days in combination with protein-bound paclitaxel given intravenously on days 1, 8 and 15 in patients with pancreas and breast cancer. One cycle will equal 28 days. MinnelideTM Capsules should be given with the patient in a fasting state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen C (monotherapy in Gastric Cancer)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Minnelide™ Capsules will be given as a single agent orally once daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days. Minnelide™ Capsules should be given with the patient in a fasting state.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minnelide™Capsules</intervention_name>
    <description>Minnelide™ is a water soluble disodium salt variant of triptolide an heat shock protein (HSP) inhibitor.</description>
    <arm_group_label>Regimen A (monotherapy)</arm_group_label>
    <arm_group_label>Regimen B (combination)</arm_group_label>
    <arm_group_label>Regimen C (monotherapy in Gastric Cancer)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Patients with histologically confirmed advanced solid tumors (regimen A), breast or
             pancreas (regimen B), or gastric cancer (regimen C)

          -  Tumor progression after receiving standard/approved chemotherapy or where there is no
             approved therapy

          -  Prior treatment with protein-bound paclitaxel allowed if it has been six months since
             received or progressed on protein-bound paclitaxel and plan to continue to receive
             protein-bound paclitaxel with MinnelideTM Capsules

          -  One or more metastatic tumors measurable per RECIST v1.1 Criteria

          -  Karnofsky performance ≥ 70%

          -  Life expectancy of at least 3 months

          -  Age ≥ 18 years

          -  Signed, written IRB-approved informed consent

          -  A negative pregnancy test (if female)

          -  Acceptable liver function:

               -  Bilirubin ≤ 1.5 times upper limit of normal

               -  AST (SGOT), ALT (SGPT) and Alkaline phosphatase ≤ 2.5 times upper limit of normal
                  (if liver metastases are present, then ≤ 5 x ULN is allowed)

               -  Albumin ≥ 3.0 g/dL

          -  Acceptable renal function:

             o Serum creatinine within normal limits, OR calculated creatinine clearance ≥ 60
             mL/min/1.73 m2 for patients with creatinine levels above institutional normal.

          -  Acceptable hematologic status:

               -  Granulocyte ≥ 1500 cells/mm3

               -  Platelet count ≥ 100,000 (plt/mm3)

               -  Hemoglobin ≥ 9 g/dL

          -  Urinalysis:

             o No clinically significant abnormalities

          -  Acceptable coagulation status:

               -  PT ≤ 1.5 times institutional ULN

               -  PTT ≤ 1.5 times institutional ULN

          -  For men and women of child-producing potential, the use of effective contraceptive
             methods during the study

        Exclusion Criteria:

          -  New York Heart Association Class III or IV, cardiac disease, myocardial infarction
             within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG

          -  Baseline QTc exceeding 470 msec (using the Bazett's formula) and/or patients receiving
             class 1A or class III antiarrhythmic agents.

          -  Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic
             therapy

          -  Pregnant or nursing women. NOTE: Women of child-bearing potential and men must agree
             to use adequate contraception (hormonal or barrier method of birth control; or
             abstinence) prior to study entry and for the duration of study participation. Should a
             woman become pregnant or suspect she is pregnant while participating in this study,
             she should inform her treating physician immediately.

          -  Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy
             within one month prior to study entry (6 weeks for nitrosoureas or Mitomycin C).

          -  Unwillingness or inability to comply with procedures required in this protocol

          -  Known infection with HIV, hepatitis B, or hepatitis C

          -  Serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other
             conditions) that could compromise protocol objectives in the opinion of the
             investigator and/or the sponsor

          -  Patients who are currently receiving any other investigational agent

          -  Patients who are on a prohibited medication (section 4.4.2).

          -  Patients with biliary obstruction and/or biliary stent (Regimen B only)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cameron Wright, MS</last_name>
    <role>Study Director</role>
    <affiliation>Translational Drug Development</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cameron Wright, MS</last_name>
    <phone>6023588341</phone>
    <email>cwright@td2inc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohana Velagapudi, MD</last_name>
    <phone>3092693132</phone>
    <email>mvelagapudi@minneamrita.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>205-934-9999</phone>
    </contact>
    <investigator>
      <last_name>Ravi K Paluri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>HonorHealth Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Schaffer, MSN,RN,AOCNS</last_name>
      <phone>480-323-1364</phone>
      <email>Joyce.schaffer@honorhealth.com</email>
    </contact>
    <investigator>
      <last_name>Erkut Borazanci, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Richardson, RN</last_name>
      <phone>310-423-2133</phone>
      <email>cancer.trial.info@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Monica Mita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 18, 2017</study_first_submitted>
  <study_first_submitted_qc>April 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

